Neuphoria Therapeutics (NEUP) Return on Sales (2024 - 2025)

Neuphoria Therapeutics (NEUP) reported Return on Sales of 11.42% for Q2 2025, up 152065.01% quarter-over-quarter from 0.01% in Q1 2025.

Neuphoria Therapeutics (NEUP) Return on Sales (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has 2 years of Return on Sales data on file, last reported at 11.42% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.00%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	0.00%
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	0.00%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Neuphoria Therapeutics	23.86 Mn	4.46 Mn	-	-

Download Data